Deletion of Exon 4 in the N-Acetylgalactosamine-4-Sulfatase Gene in a Taiwanese Patient with Mucopolysaccharidosis Type VI

被引:6
作者
Lin, Wei-De [1 ,2 ]
Ke, Yu-Yuan [3 ]
Chou, I-Ching [4 ,5 ]
Wang, Chung-Hsing [4 ,6 ]
Tsai, Fuu-Jen [4 ,7 ,8 ,9 ]
机构
[1] China Med Univ Hosp, Dept Med Res, Taichung 404, Taiwan
[2] China Med Univ, Sch Post Baccalaureate Chinese Med, Taichung, Taiwan
[3] Taichung Vet Gen Hosp, Dept Pediat, Taichung, Taiwan
[4] China Med Univ Hosp, Dept Pediat, Taichung 404, Taiwan
[5] China Med Univ, Grad Inst Integrated Med, Taichung, Taiwan
[6] China Med Univ, Sch Med, Taichung, Taiwan
[7] China Med Univ Hosp, Dept Med Genet, Taichung 404, Taiwan
[8] China Med Univ, Sch Chinese Med, Taichung, Taiwan
[9] Asia Univ, Dept Hlth & Nutr Biotechnol, Taichung, Taiwan
关键词
deletion mutation; dermatan sulfate accumulation; enzyme replacement therapy; mucopolysaccharidosis type VI; N-acetylgalactosamine-4-sulfatase; ENZYME REPLACEMENT THERAPY; MAROTEAUX-LAMY SYNDROME; HUMAN ARYLSULFATASE-B; LYSOSOMAL STORAGE DISEASES; MOLECULAR ANALYSIS; CLONING; CDNA; FORM;
D O I
10.1620/tjem.235.267
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Mucopolysaccharidosis type VI (MPS VI) is a rare autosomal recessive disorder caused by a deficiency of N-acetylgalactosamine-4-sulfatase (ARSB), one of the enzymes required for the degradation of dermatan sulfate (DS). Accumulation of DS in connective tissue causes growth failure, resulting in short stature. Here, we observed a 5-year-old girl who was the only one affected member of her family and who presented with an exaggerated, convex curvature of the back at the age of one year. Abnormal excretion of DS in the urine and extremely low leukocyte ARSB activity were noted. The patient was suspected to have MPS VI. Direct DNA sequencing indicated that there was no mutation in the coding region of ARSB. However, RT-PCR analysis of RNA prepared from blood samples indicated the deletion of the entire exon 4. Further analysis of the genonnic DNA by quantitative PCR confirmed a homozygous deletion of exon 4, an unusual intragenic deletion in ARSB. The deletion led to a truncated protein that lacks most of the catalytic domain. The patient received recombinant human ARSB as enzyme replacement therapy (ERT) at an early stage (2 years), and responded positively in terms of skeletal development and other developmental milestones. The early identification of type VI MPS patients and subsequent treatment with ERT may be beneficial for the clinical outcome of MPS VI patients. In addition, detailed gene analysis may enhance the ability to provide genetic counseling to families of patients affected by MPS VI.
引用
收藏
页码:267 / 273
页数:7
相关论文
共 27 条
  • [1] [Anonymous], 2001, The metabolic basis of inherited disease
  • [2] ARLT G, 1994, J BIOL CHEM, V269, P9638
  • [3] Structure of a human lysosomal sulfatase
    Bond, CS
    Clements, PR
    Ashby, SJ
    Collyer, CA
    Harrop, SJ
    Hopwood, JJ
    Guss, JM
    [J]. STRUCTURE, 1997, 5 (02) : 277 - 289
  • [4] An index case for the attenuated end of the mucopolysaccharidosis type VI clinical spectrum
    Brooks, DA
    Gibson, GJ
    Karageorgos, L
    Hein, LK
    Robertson, EF
    Hopwood, JJ
    [J]. MOLECULAR GENETICS AND METABOLISM, 2005, 85 (03) : 236 - 238
  • [5] Ceulemans S, 2012, METHODS MOL BIOL, V838, P311, DOI 10.1007/978-1-61779-507-7_15
  • [6] Genetic studies in a cluster of Mucopolysaccharidosis Type VI patients in Northeast Brazil
    Costa-Motta, Fabiana Moura
    Acosta, Angelina Xavier
    Abe-Sandes, Kiyoko
    Bender, Fernanda
    Schwartz, Ida Vanessa D.
    Giugliani, Roberto
    Leistner-Segal, Sandra
    [J]. MOLECULAR GENETICS AND METABOLISM, 2011, 104 (04) : 603 - 607
  • [7] Fidzianska E, 1990, Probl Med Wieku Rozwoj, V16, P163
  • [8] Enzyme replacement therapy attenuates disease progression in two Japanese siblings with mucopolysaccharidosis type VI
    Furujo, Mahoko
    Kubo, Toshihide
    Kosuga, Motomichi
    Okuyama, Torayuki
    [J]. MOLECULAR GENETICS AND METABOLISM, 2011, 104 (04) : 597 - 602
  • [9] Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome)
    Harmatz, P
    Whitley, CB
    Waber, L
    Pais, R
    Steiner, R
    Plecko, B
    Kaplan, P
    Simon, J
    Butensky, E
    Hopwood, JJ
    [J]. JOURNAL OF PEDIATRICS, 2004, 144 (05) : 574 - 580
  • [10] Enzyme replacement therapy for mucopolysaccharidosis VI: A Phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study
    Harmatz, Paul
    Giugliani, Roberto
    Schwariz, Ida
    Guffon, Nathaue
    Teles, Eusa Leao
    Miranda, M. Clara Sa
    Wraith, J. Edmond
    Beck, Michael
    Arash, Lapp
    Scarpa, Maurilo
    Yu, Zi-Fan
    Wittes, Janet
    Berger, Kenneth I.
    Newman, Mary S.
    Lowe, Ann M.
    Kakkis, Emil
    Swiedler, Stuart J.
    [J]. JOURNAL OF PEDIATRICS, 2006, 148 (04) : 533 - 539